NNNN on Nasdaq

Anbio Biotechnology

Price unavailable

Last updated Oct 16, 2026.

Overview

$8.6MRevenue, fiscal 20252
$6.4MNet income, fiscal 20252

Compare with Aspira Women's Health Inc., BIOMERICA INC or Insight Molecular Diagnostics Inc., or pick any stock.

  • TickerNNNN on Nasdaq
  • IndustryIn Vitro & In Vivo Diagnostic Substances
  • HeadquartersE9
  • Incorporated inCayman Islands3
  • Business addressFriedrich-Ebert-Anlage 49, Frankfurt Am Main, 2M 603083
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

87.2%Gross margin2
66.7%Operating margin2
74.1%Net margin2
5.6%Revenue growth, 20252
21.2%Return on equity2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

European Union brought in 60% of the revenue Anbio Biotechnology broke down this way in fiscal 2025.

  1. European Union$5.2M260%down 8% from 2024
  2. Asia Pacific$1.5M218%up 199% from 2024
  3. Other Regions$1.4M216%up 198% from 2024
  4. North America$296.2K23%up 168% from 2024
  5. South America$269.5K23%down 82% from 2024
Regions by year
Regions202320242025
European Union$4.7M$5.6M$5.2M
Asia Pacific$73.4K$509.2K$1.5M
Other Regions$111.0K$472.4K$1.4M
North America$215.4K$110.5K$296.2K
South America$1.7M$1.5M$269.5K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue12¢$1.1M
  • Research and development2¢$201.3K
  • Selling, general and admin17¢$1.6M
  • Profit69¢$6.4M

Out of $8.6M in revenue.2

Financial statements

Revenue42$8.6M in 2025−63% since 2022
0$10.0M$20.0M$30.0M2022: $23.5M$23.5M20222023: $6.7M$6.7M2023−71%2024: $8.2M$8.2M2024+22%2025: $8.6M$8.6M2025+6%
Gross profit42$7.5M in 2025−40% since 2022
0$5.0M$10.0M$15.0M2022: $12.6M$12.6M20222023: $3.4M$3.4M2023−73%2024: $5.9M$5.9M2024+75%2025: $7.5M$7.5M2025+28%
Operating income42$5.8M in 2025−43% since 2022
0$5.0M$10.0M$15.0M2022: $10.2M$10.2M20222023: $2.0M$2.0M2023−81%2024: $2.0M$2.0M2024+2%2025: $5.8M$5.8M2025+189%
Net income42$6.4M in 2025−36% since 2022
0$5.0M$10.0M$15.0M2022: $10.0M$10.0M20222023: $2.3M$2.3M2023−77%2024: $2.4M$2.4M2024+5%2025: $6.4M$6.4M2025+170%
Fiscal year20212022202320242025
Revenue$23.5M4$6.7M2$8.2M2$8.6M2
Cost of revenue$11.0M4$3.4M2$2.3M2$1.1M2
Gross profit$12.6M4$3.4M2$5.9M2$7.5M2
Research and development$200.0K4$134.7K2$454.2K2$201.3K2
Selling, general and admin$2.2M4$1.3M2$3.4M2$1.6M2
Operating income$10.2M4$2.0M2$2.0M2$5.8M2
Income tax$02$02$02
Net income$10.0M4$2.3M2$2.4M2$6.4M2
Earnings per share$100,112.004$0.102$0.062$0.152
Earnings per share (diluted)$100,112.004$0.102$0.062$0.152

Compare Anbio Biotechnology with another company

Recent filings

  1. Jul 9, 2026F-3ASR AUTOMATIC SHELF REGISTRATION STATEMENT OF SECURITIES OF WELL-KNOWN SEASONED ISSU
  2. Jun 12, 20263
  3. Jun 12, 20263
  4. May 19, 20266-K
  5. Apr 27, 20266-K
  6. Apr 9, 202620-F/A FORM 20-F/A1
  7. Apr 8, 20263
  8. Apr 8, 20263
  9. Apr 8, 20263
  10. Apr 8, 20263
  11. Apr 8, 20263
  12. Apr 7, 202620-F
  13. Feb 17, 20266-K
  14. Jan 26, 20266-K
  15. Dec 30, 20256-K REPORT OF FOREIGN PRIVATE ISSUER

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4